News Column

Integral Molecular Reports Patent Allowance for Dengue Research Technology

July 23, 2014

Integral Molecular reported the issuance of a new composition patent protecting dengue reporter virus particles (RVPs).

According to a release, the invention relates to the company's chimeric and codon-optimized flavivirus replicons, expression plasmids, and RVPs used for infectivity, neutralization, enhancement and structure-function studies of dengue virus (DENV) and its envelope protein (prM/E). U.S. Patent No 8,691,961, was issued by the USPTO on April 8, furthering the company's commitment to the discovery of drugs and vaccines against this widespread virus.

"The dengue virus RVPs are enabling faster and more accurate quantification of dengue sera and antibody neutralization and enhancement," said Benjamin Doranz, Chief Scientific Officer at Integral Molecular. "The technology is also being used in our structural studies of DENV envelope, for instance, to identify the exact residues responsible for mediating its folding, triggering, and fusion."

Integral Molecular has a long-standing interest in dengue research, and has epitope mapped over 150 monoclonal antibodies targeting dengue envelope proteins as part of an ongoing contract funded by the National Institute of Allergy and Infectious Diseases (NIAID).

Integral Molecular offers dengue virus RVPs that retain antigenic equivalence to wild-type virions by incorporating prM/E proteins from DENV serotypes 1, 2, 3, or 4. DENV RVPs feature a reporter gene that provides a rapid and convenient read-out of infectivity, and are validated for both antibody neutralization and enhancement studies. Epitope mapping of anti-viral antibodies by Shotgun Mutagenesis is offered on a fee-for-service basis.

Integral Molecular is a research-driven biotechnology company.

More information and complete details:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Professional Services Close - Up

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters